Our mission is to become a worldwide reference for education in the field for all professionals involved in the process to dissemintate knowledge & skills of Acute Cardiovascular Care
Our mission is to promote excellence in clinical diagnosis, research, technical development, and education in cardiovascular imaging in Europe.
Our mission: To promote excellence in research, practice, education and policy in cardiovascular health, primary and secondary prevention.
Our goal is to reduce the burden in cardiovascular disease in Europe through percutaneous cardiovascular interventions.
Our Mission is "to improve the quality of life of the population by reducing the impact of cardiac rhythm disturbances and reduce sudden cardiac death"
To improve quality of life and logevity, through better prevention, diagnosis and treatment of heart failure, including the establishment of networks for its management, education and research.
Working Groups goals is to stimulate and disseminate scientific knowledge in different fields of cardiology.
ESC Councils goal is to share knowledge among medical professionals practising in specific cardiology domains.
OUR MISSION: TO REDUCE THE BURDEN OF CARDIOVASCULAR DISEASE
Jeroen J. Bax
During this session, the 6 new ESC guidelines for 2012 were presented.
The first presentation included the new guideline on cardiovascular disease prevention. This guideline was presented by professor Joep Perk (Sweden), who highlighted that of all deaths that occur in Europe before the age of 75 years, 42% in women are due to cardiovascular disease and 38% in men. Conversely, 50% of the reductions in cardiovascular mortality are due to reduction in risk factors and 40% due to improved treatments. The current new guideline has been accomplished with various different societies and has put forward important emphasis and recommendations on improvement in risk factors. The second guideline concerned heart failure. Professor John McMurray (UK) indicated that the new guideline linked recommendations to treatment effects. Specifically, new information was provided on innovations in pharmaceutical and device therapy, but also on improved diagnostic and prognostic assessment (with advanced biomarkers and imaging modalities). Also, clear definitions on systolic versus diastolic heart failure were included. The third presentation addressed the new guideline on STEMI, and was presented by the co-chairs professors Stefan James (Sweden) and Gabriel Steg (France). The presenters highlighted the improvements in early diagnosis, prehospital logistics of care and better treatment definition in cardiac arrest. Also, they eluded on the modifications on maximal time delays and the timing of angiography after thrombolysis. They also discussed on stent recommendations and anti-thrombotic therapy. The fourth presentation concerned the 3rd universal definition of myocardial infarction, chaired by professors Joseph Alpert (USA), Kristian Thygesen (Denmark) and Harvey White (New Zealand); this task force is a collaboration between different associations from the USA, Europe and Asia. This presentation was organized along the improved definitions of the 5 types of myocardial infarction and their clinical implications. The fifth guideline was on valvular disease, highlighting a collaboration between the European Association of CardioThoracic Surgery (EACTS) and the ESC. The presentation was initiated by professor Alec Vahanian (France) addressing the new recommendations in aortic valve disease, and (for the first time) with recommendations on TAVI. The second part was presented by professor Ottavio Alfieri (Italy) on the novel and expanded recommendations in mitral (and tricuspid) valve disease. The sixth and last presentation concerned the short update on atrial fibrillation, presented by professor John Camm (UK); the main highlights included the recommendations on the use of novel oral anticoagulations, modified recommendations in anti-arrhythmic therapy and suggestions for the role of catheter ablation.
2012 Guidelines overview